Investigating how a specific protein affects ovarian cancer progression
Role of exosomal SPHK1 in ovarian cancer progression
['FUNDING_R01'] · MEDICAL COLLEGE OF WISCONSIN · NIH-11015075
This study is looking at how a specific protein called SPHK1 affects the immune system's ability to fight ovarian cancer, with the hope of finding ways to make immunotherapy work better for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MEDICAL COLLEGE OF WISCONSIN (nih funded) |
| Locations | 1 site (MILWAUKEE, UNITED STATES) |
| Trial ID | NIH-11015075 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of sphingosine kinase 1 (SPHK1) in ovarian cancer and how it influences the immune response against tumors. The study examines how SPHK1 is packaged in extracellular vesicles and its impact on the tumor microenvironment, particularly in relation to immune checkpoint inhibitors. By analyzing blood samples from ovarian cancer patients, the research aims to uncover mechanisms that could enhance the effectiveness of immunotherapy for this type of cancer. The ultimate goal is to develop strategies that encourage the immune system to better recognize and attack ovarian cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with ovarian cancer who may benefit from new immunotherapy approaches.
Not a fit: Patients with non-cancerous conditions or those not diagnosed with ovarian cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for ovarian cancer patients.
How similar studies have performed: While immunotherapy has shown success in other cancers, this specific approach targeting SPHK1 in ovarian cancer is relatively novel and has not been extensively tested.
Where this research is happening
MILWAUKEE, UNITED STATES
- MEDICAL COLLEGE OF WISCONSIN — MILWAUKEE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PRADEEP, SUNILA — MEDICAL COLLEGE OF WISCONSIN
- Study coordinator: PRADEEP, SUNILA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy